Opinion
Antagna on 28/03/2012
Dokumentreferens:
INT/639-EESC-2012-812Referral:
COM(2012) 51 final - 2012/0023 (COD)Plenarsession:
479 -
Mar 28, 2012 Mar 29, 2012
Läkemedel
Displaying 11 - 20 of 25
Pages
Opinion
Antagna on 28/03/2012
Dokumentreferens:
INT/637-EESC-2012-810Referral:
COM(2012) 49 final - 2008/0255 (COD)Plenarsession:
479 -
Mar 28, 2012 Mar 29, 2012
Opinion
Antagna on 28/03/2012
Dokumentreferens:
INT/636-EESC-2012-809Referral:
COM(2012) 48 final - 2008/0256 (COD)Plenarsession:
479 -
Mar 28, 2012 Mar 29, 2012
Opinion
Antagna on 22/02/2012
Dokumentreferens:
INT/602-EESC-2012-469Referral:
COM(2011) 633 final - 2008/0256 (COD)Plenarsession:
478 -
Feb 22, 2012 Feb 23, 2012
Opinion
Antagna on 22/02/2012
Dokumentreferens:
INT/601-EESC-2012-468Referral:
COM(2011) 632 final - 2008/0255 (COD)Plenarsession:
478 -
Feb 22, 2012 Feb 23, 2012
Opinion
Antagna on 30/09/2009
Dokumentreferens:
INT/478-EESC-2009-1456Referral:
COM(2008) 666 finalRapporteur:
Plenarsession:
456 -
Sep 30, 2009 Oct 01, 2009
Opinion
Antagna on 15/07/2009
Dokumentreferens:
TEN/378-EESC-2009-1197Referral:
COM(2008) 689 finalRapporteur:
Mr Lucien Bouis (Diversity Europe - GR III / France)
Plenarsession:
455 -
Jul 15, 2009 Jul 16, 2009
Opinion
Antagna on 15/07/2009
Dokumentreferens:
INT/472-EESC-2009-1191Referral:
COM(2008) 668 final - 2008/0261 (COD)Rapporteur:
Plenarsession:
455 -
Jul 15, 2009 Jul 16, 2009
Opinion
Antagna on 10/06/2009
Dokumentreferens:
INT/469-EESC-2009-1022Referral:
COM(2008) 663 final - 2008/0256 (COD)Rapporteur:
Plenarsession:
454 -
Jun 10, 2009 Jun 11, 2009